기본 정보
- CAS
135070-05-2- 표준 SMILES
Cc1ccnc2c1nc(C1CC1)n2Cc1ccc(-c2ccccc2C(=O)O)cc1- InChIKey
VWWMGPCUZVOLLK-UHFFFAOYSA-N- 분자식
- C24H21N3O2
- 평균 분자량
- 383.4 g/mol
- 단동위원소 질량
- 383.16337691
개요
a non-peptide angiotensin II-receptor antagonist; structure given in first source
이름 및 식별자
- 우선 이름
- 3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine
- IUPAC
- 2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid
- 영어명
- E 4177
- 분자식
- C24H21N3O2
- 분자량
- 383.449
이름 및 동의어
135070-05-2E41773-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine(1,1'-Biphenyl)-2-carboxylic acid, 4'-((2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridin-3-yl)methyl)-RefChem:91968E-4177E 41772-[4-[(8-cyclopropyl-5-methyl-2,7,9-triazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)methyl]phenyl]benzoic acidCHEMBL711622-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid57G709; E 14774'-((2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
이름 더 보기
1,1'-Biphenyl]-2-carboxylic acid, 4'-[(2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-
VWWMGPCUZVOLLK-UHFFFAOYSA-NSCHEMBL685515orb1700680SCHEMBL30838455DTXSID50159239BDBM50049212AKOS040748296CS-0026848
데이터베이스 식별자
- CAS
135070-05-2- PubChem CID
- 131857
- DTXSID
DTXSID50159239- ChEMBL
CHEMBL71162- Nikkaji
- J551.227A
물성
구조 계산 물성
- XLogP
- 4.4
- 극성 표면적
- 68 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 4
- 회전 가능 결합 수
- 5
- 무거운 원자 수
- 29
- 형식 전하
- 0
- 복잡도
- 587
화학 및 산업
약리 정보
MeSH Pharmacological ClassificationAgents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
공급사4 곳
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
济南睿思医药技术有限公司0531-0531-69900633 19963472814 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
上海阿摩尔生物科技有限公司13370042665 18916960931 · [email protected]
관련 반응
6건
화합물 노트
불러오는 중…